Brazil faces challenges delivering hepatitis B vaccines across vast regions of the Amazon and the North, where limited transportation and sparse health services hinder vaccination and medical follow-up. The country recorded approximately 4,600 confirmed hepatitis B cases in 2025, according to the Ministry of Health.
Most adults spontaneously clear hepatitis B infection. Infection in early childhood, however, carries a much higher risk of becoming chronic. When the body cannot eliminate the virus, it persists in liver cells and can progress to cirrhosis, liver failure, and liver cancer.
Current medications like tenofovir and entecavir reduce viral replication and lower complication risk. Yet controlling the virus differs from eliminating it. The hepatitis B virus converts its DNA into a stable circular molecule called cccDNA that acts as a viral reservoir in the cell nucleus. Integrated viral sequences can continue producing the virus's surface antigen, known as HBsAg. Viral proteins trigger the chronic immune response that damages the liver.
Researchers at Fundação Oswaldo Cruz tested RNA interference, or RNAi, a strategy using small RNA molecules to intercept and destroy messenger RNA before it produces viral proteins. Giovana Angelice and colleagues introduced hepatitis B virus RNA into cultured liver cells and tested RNAi-based candidates. One candidate reduced HBsAg levels in the cell cultures.
The result remains preliminary. The cultured cell model does not replicate all stages of natural infection. Researchers now collaborate with KU Leuven in Belgium to test RNAi in cellular models and hamsters that better mimic hepatitis B infection. The research aims to verify whether silencing persists in complex systems.
RNAi will likely not eliminate all viral reservoirs but may contribute to more effective, long-lasting disease control when used alongside existing medications. Years of research remain before testing in patients.